<DOC>
	<DOCNO>NCT00521300</DOCNO>
	<brief_summary>The purpose study investigate whether 6 month preoperative treatment somatostatin analogue octreotide improve surgical outcome patient acromegaly .</brief_summary>
	<brief_title>Preoperative Octreotide Treatment Acromegaly</brief_title>
	<detailed_description>After baseline evaluation , patient randomize separately study center block four directly transsphenoidal surgery 6-month preoperative treatment octreotide . To reduce risk gastrointestinal adverse effect pretreatment group , octreotide initiate dose 50 µg sc three time day 1st week 100 µg sc three time day 2nd week . From 3rd week , patient receive octreotide LAR ( Novartis International AG , Basel , Switzerland ) 20 mg im every 28th day 6 month . Patients receive transsphenoidal surgery within 28 last injection . If surgery delayed , extra octreotide LAR injection give surgery .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Growth Hormone-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>GH nadir standard 75 g OGTT &gt; = 5.0 mmol/L . Pituitary tumor MRIscan . Immediate surgery indicate usual clinical criterion . Pregnant . Known adverse effect octreotide . Unfit participation reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Acromegaly</keyword>
</DOC>